公开(公告)号：US20230228741A1

公开(公告)日：2023-07-20

申请号：US17763572

申请日：2020-09-23

Applicant: Sengenics Corporation Pte Ltd ,  Agency for Science, Technology and Research

Inventor： Jonathan Michael BLACKBURN ,  Arif ANWAR ,  Nurul H. RUTT ,  Anis LARBI ,  Olivier Nicolas Felix CEXUS ,  Bernett LEE ,  Jesus Felix Bayta VALENZUELA ,  Christopher MONTEROLA ,  Victor TONG

IPC: G01N33/50 ,  G01N33/564 ,  G01N33/68

CPC classification number: G01N33/5091 ,  G01N33/564 ,  G01N33/6875 ,  G01N2333/70596 ,  G01N2800/00

Abstract: A method for determining the health status of an elderly individual by testing the sample extracted from the individual for the presence of biomarkers, the bio markers being autoantibodies to antigens comprising MAPK13, CD96, FKBP3, PPM1A, PHLDA1, GLRX3, FEN1 and AURKA, wherein the antigens may further comprise one or more of UBE2I, AAK1, YARS, ASPSCR1, CASP10, FHOD2, TCL1A and MAP4, wherein PHLDA1 and CD96 correspond to healthy, AURKA, FEN1, CASP10 and AAK1 correspond to intermediate health, and UBE2I, YARS, ASPSCR1, FHOD2, TCL1A, MAP4, MAPK13, FKBP3, PPM1A and GLRX3 correspond to unhealthy.

公开(公告)号：US20240369555A1

公开(公告)日：2024-11-07

申请号：US18773218

申请日：2024-07-15

Applicant: Agency for Science, Technology and Research

Inventor： Guillaume Robert CARISSIMO ,  Immanuel Kwok Weng HAN ,  Weili XU ,  Lisa Fong Poh NG ,  Laurent RENIA ,  Anis LARBI ,  Lai Guan NG

IPC: G01N33/569 ,  A61K49/00 ,  G01N33/50

Abstract: There is provided a method of evaluating risk of severe outcome of an infectious disease and/or an inflammatory disease in a patient, the method comprising: determining/measuring the number of one or more immune cells selected from the group consisting of VD2 T cells, CD8 T cells, and immature neutrophils in a sample obtained from the patient, wherein the patient has an enhanced risk of severe infectious disease and/or inflammatory disease outcome when: (i) the ratio of immature neutrophils to VD2 T cell is at least 2:1, and/or (ii) the ratio of immature neutrophils to CD8 T cell is at least 0.5:1. Also disclosed are method of treating a patient with a severe infectious disease and/or inflammatory disease and kit for use in methods thereof.

公开(公告)号：US20220187296A1

公开(公告)日：2022-06-16

申请号：US17117455

申请日：2020-12-10

Applicant: Agency for Science, Technology and Research

Inventor： Guillaume Robert CARISSIMO ,  Immanuel Kwok Weng HAN ,  Weili XU ,  Lisa Fong Poh NG ,  Laurent RENIA ,  Anis LARBI ,  Lai Guan NG

IPC: G01N33/569

Abstract: There is provided a method of evaluating risk of severe outcome of an infectious disease and/or an inflammatory disease in a patient, the method comprising: determining/measuring the number of one or more immune cells selected from the group consisting of VD2 T cells, CD8 T cells, and immature neutrophils in a sample obtained from the patient, wherein the patient has an enhanced risk of severe infectious disease and/or inflammatory disease outcome when: (i) the ratio of immature neutrophils to VD2 T cell is at least 2:1, and/or (ii) the ratio of immature neutrophils to CD8 T cell is at least 0.5:1. Also disclosed are method of treating a patient with a severe infectious disease and/or inflammatory disease and kit for use in methods thereof.